Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Clinical trial NCT06253650 · RECRUITING
Trial details
- NCT number
- NCT06253650
- Sponsor
- Gruppo Oncologico del Nord-Ovest
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-01
- Primary completion
- 2027-03-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.